The specific JAK2 inhibitor TG101209 is also a MYB suppressor in Burkitt lymphoma, and the JAK1/2 inhibitor ruxolitinib is currently applied for the treatment of JAK-STAT-dependent neoplasms (including JAK2V617F forms), but with limited efficacy based on cytoprotective autophagy induction both in JAK2-wildtype (HL-60) and in JAK2V617F cells (HEL)[176,198]. This evidence concerns the gene MYB and Burkitt lymphoma.